Gerhard, Angela
Rosenow, Felix http://orcid.org/0000-0002-3989-7471
Möckel, Luis http://orcid.org/0000-0002-1338-8433
Jöres, Lars
Ma, Yuanjun
Liou, Heidi Shiow Chyong
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Funding for this research was provided by:
UCB Pharma Germany
Article History
Received: 1 May 2024
Accepted: 11 June 2024
First Online: 2 July 2024
Declarations
:
: This work was supported by UCB Pharma. UCB Pharma was involved in the design of the study, the analysis and interpretation of data, and in the decision to publish the manuscript. Luis Möckel, Lars Jöres, Yuanjun Ma, and Heidi Shiow Chyong Liou are current or past employees of UCB Pharma, and Luis Möckel, Lars Jöres, and Yuanjun Ma have received UCB Pharma stocks from their employment. Felix Rosenow received honoraria for presentations and/or scientific advice from Angelini Pharma, Desitin Pharma, Eisai GmbH, Roche Pharma and UCB Pharma. He received research support from German Research Foundation, German Federal Ministry for Education and Research, Hessonian Ministry of Science and Arts including through its LOEWE Program, Hessonian Ministry for Social Affairs and Integration, Chaja Foundation, Reiss Foundation, Dr. Senkenbergische Foundation, and Detlev-Wrobel Fonds for Epilepsy Research Frankfurt. Adam Strzelczyk reported receiving personal fees from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, Marinus Pharma, UNEEG Medical, UCB Pharma, and Zogenix as well as grants from Zogenix and GW Pharmaceuticals. Angela Gerhard has nothing to declare.
: This study was conducted in accordance with national data protection regulations and the Declaration of Helsinki. As a result of the nature of the data, it was not possible to obtain patient consent for usage of the data in this analysis. The analysis was based on emergency data and the emergency situation did not allow consent to be requested. The data was stored with minimum personal information (age and county) and no names were available to identify the patients to obtain retrospective patient consent. In addition, patient consent for retrospective analysis of anonymized, secondary data is not mandatory. Finally, a review board of the HSD Hochschule Döpfer Cologne, Germany, reviewed the protocol and decided that patient consent based on the available data was not necessary. The conduct of this study using public data for neurologic disorders was also approved by the ethical commission of the Faculty of Medicine of Goethe University Frankfurt (application reference 313/16).